Paper32344648
Inhibiting Monocyte Recruitment to Prevent the Pro-Tumoral Activity of Tumor-Associated Macrophages in Chondrosarcoma.
Minopoli M and 15 others. Cells, 2020. Cited by 21 papers, by iCite.
Cite this record
ConductScience Library. Inhibiting Monocyte Recruitment to Prevent the Pro-Tumoral Activity of Tumor-Associated Macrophages in Chondrosarcoma. Papers, record 32344648. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32344648
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Inhibiting Monocyte Recruitment to Prevent the Pro-Tumoral Activity of Tumor-Associated Macrophages in Chondrosarcoma.
- PubMed
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Chondrosarcoma | Major topic |
| Monocytes | Major topic |
| Tumor-Associated Macrophages | Major topic |
| Adult | |
| Aged | |
| Animals | |
| Antigens, CD | |
| Collagen | |
| Female | |
| Fibroblasts | |
| Human Umbilical Vein Endothelial Cells | |
| Humans | |
| Immunophenotyping | |
| Male | |
| Mice, Nude | |
| Microvessels | |
| Middle Aged | |
| Phenotype | |
| Spheroids, Cellular | |
| THP-1 Cells | |
| Time Factors |
Source PubMed
References64
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 24319632 | Cancer-associated fibroblasts and macrophages: Friendly conspirators for malignancy. | Oncoimmunology | 2013 | https://conductscience.org/library/papers/24319632 | PubMed |
| 2 | 31915413 | Prognostic Factors in Dedifferentiated Chondrosarcoma: A Retrospective Analysis of a Large Series Treated at a Single Institution. | Sarcoma | 2019 | https://conductscience.org/library/papers/31915413 | PubMed |
| 3 | 27482883 | The impact of hypoxia on tumor-associated macrophages. | J Clin Invest | 2016 | https://conductscience.org/library/papers/27482883 | PubMed |
| 4 | 16400033 | Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. | Am J Pathol | 2006 | https://conductscience.org/library/papers/16400033 | PubMed |
| 5 | 15866865 | Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide. | J Biol Chem | 2005 | https://conductscience.org/library/papers/15866865 | PubMed |
| 6 | 32274326 | Corrigendum to: ``The immune landscape of chondrosarcoma reveals an immunosuppressive environment in the dedifferentiated subtypes and exposes CSFR1+ macrophages as a promising therapeutic target.'' J Bone Oncol. 2020 Feb; 20: 100271. | J Bone Oncol | 2020 | https://conductscience.org/library/papers/32274326 | PubMed |
| 7 | 29216889 | Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells. | J Exp Clin Cancer Res | 2017 | https://conductscience.org/library/papers/29216889 | PubMed |
| 8 | 25614318 | Immune cell promotion of metastasis. | Nat Rev Immunol | 2015 | https://conductscience.org/library/papers/25614318 | PubMed |
| 9 | 2191922 | Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. | Int J Pept Protein Res | 1990 | https://conductscience.org/library/papers/2191922 | PubMed |
| 10 | 16864600 | Dual role of macrophages in tumor growth and angiogenesis. | J Leukoc Biol | 2006 | https://conductscience.org/library/papers/16864600 | PubMed |
| 11 | 22674453 | Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma. | Genes Chromosomes Cancer | 2012 | https://conductscience.org/library/papers/22674453 | PubMed |
| 12 | 28133974 | Novel therapeutic approaches in chondrosarcoma. | Future Oncol | 2017 | https://conductscience.org/library/papers/28133974 | PubMed |
| 13 | 24812208 | The cellular and molecular origin of tumor-associated macrophages. | Science | 2014 | https://conductscience.org/library/papers/24812208 | PubMed |
| 14 | 18378543 | The clinical approach towards chondrosarcoma. | Oncologist | 2008 | https://conductscience.org/library/papers/18378543 | PubMed |
| 15 | 31642585 | Crosstalk between cancer-associated fibroblasts and immune cells in cancer. | J Cell Mol Med | 2020 | https://conductscience.org/library/papers/31642585 | PubMed |
| 16 | 21249423 | Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. | Cancer Metastasis Rev | 2011 | https://conductscience.org/library/papers/21249423 | PubMed |
| 17 | 23185575 | Regulation of the formyl peptide receptor 1 (FPR1) gene in primary human macrophages. | PLoS One | 2012 | https://conductscience.org/library/papers/23185575 | PubMed |
| 18 | 9402652 | Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. | Stem Cells | 1997 | https://conductscience.org/library/papers/9402652 | PubMed |
| 19 | 30361552 | Targeting macrophages: therapeutic approaches in cancer. | Nat Rev Drug Discov | 2018 | https://conductscience.org/library/papers/30361552 | PubMed |
| 20 | 21614026 | The Hedgehog's tale: developing strategies for targeting cancer. | Nat Rev Cancer | 2011 | https://conductscience.org/library/papers/21614026 | PubMed |
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 21 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42738409 | The Immune Landscape of Chondrosarcoma: A Review of Tumor-Related Immune Cells. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42738409 | PubMed |
| 41827826 | Vasculogenic Mimicry: A Potential Therapeutic Target for Chondrosarcoma Therapy. | Cells | 2026 | https://conductscience.org/library/papers/41827826 | PubMed |
| 41357670 | Musculoskeletal Diseases: Mechanisms and Therapeutic Advances. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/41357670 | PubMed |
| 40960554 | The benefits of combining an immunomodulator with a chemotherapy agent in chondrosarcoma-a proof of concept with mifamurtide. | Med Oncol | 2025 | https://conductscience.org/library/papers/40960554 | PubMed |
| 40867318 | Advances in the Molecular Biology of Chondrosarcoma for Drug Discovery and Precision Medicine. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40867318 | PubMed |
| 40382743 | Exploring the causal relationship between immune factors and chondrosarcoma: a Mendelian randomization study. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40382743 | PubMed |
| 40004005 | Chondrosarcoma: New Molecular Insights, Challenges in Near-Patient Preclinical Modeling, and Therapeutic Approaches. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40004005 | PubMed |
| 38891109 | Emerging Treatments Targeting the Tumor Microenvironment for Advanced Chondrosarcoma. | Cells | 2024 | https://conductscience.org/library/papers/38891109 | PubMed |
| 38691208 | pDNA-tachyplesin treatment stimulates the immune system and increases the probability of apoptosis in MC4-L2 tumor cells. | Amino Acids | 2024 | https://conductscience.org/library/papers/38691208 | PubMed |
| 37871911 | SKP2 Knockout in Rb1/p53-Deficient Mouse Models of Osteosarcoma Induces Immune Infiltration and Drives a Transcriptional Program with a Favorable Prognosis. | Mol Cancer Ther | 2024 | https://conductscience.org/library/papers/37871911 | PubMed |
| 37745839 | Role of immunotherapy in chondrosarcoma: A case report and review of the literature. | Ther Adv Med Oncol | 2023 | https://conductscience.org/library/papers/37745839 | PubMed |
| 37468765 | Myriocin suppresses tumor growth by modulating macrophage polarization and function through the PI3K/Akt/mTOR pathway. | Arch Pharm Res | 2023 | https://conductscience.org/library/papers/37468765 | PubMed |
| 37443711 | Monocytes in Tumorigenesis and Tumor Immunotherapy. | Cells | 2023 | https://conductscience.org/library/papers/37443711 | PubMed |
| 35158766 | Therapeutic Strategies Targeting Urokinase and Its Receptor in Cancer. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35158766 | PubMed |
| 34307011 | In vitro three-dimensional cell cultures for bone sarcomas. | J Bone Oncol | 2021 | https://conductscience.org/library/papers/34307011 | PubMed |
| 34209309 | Crosstalk between Macrophages and Myxoid Liposarcoma Cells Increases Spreading and Invasiveness of Tumor Cells. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34209309 | PubMed |
| 32470379 | Modulation of the tumor microenvironment by natural agents: implications for cancer prevention and therapy. | Semin Cancer Biol | 2022 | https://conductscience.org/library/papers/32470379 | PubMed |
Genes18
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32344648
GET https://conductscience.org/api/papers/v1/32344648/references?page=2